𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder

✍ Scribed by Jean-Pierre Lindenmayer; Akbar Khan; Mariëlle Eerdekens; Ilse Van Hove; Stuart Kushner

Book ID
118436786
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
443 KB
Volume
17
Category
Article
ISSN
0924-977X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of long-acting rispe
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
✍ Robert A. Lasser; Cynthia A. Bossie; Young Zhu; Georges Gharabawi; Mariëlle Eerd 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

## Abstract ## Background Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ## Objective To assess the effi

Remission in schizophrenia: one-year Ita
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder
✍ Alessandro Rossi; Anna Bagalà; Vincenzo Del Curatolo; Francesco Scapati; Micaela 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract ## Objectives To evaluate the maintenance of efficacy of risperidone long‐acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders. The prevalence of patients who met standardized remission criteria will be also evaluated as well as the predictors fac